Personalizing Gastric Cancer Care With HER2-Targeted and Other Novel Therapies

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

Advances in HER2-Targeted and Other Novel Agents for Gastric Cancer

0.5 CME/MOC

Watch David H. Ilson, MD, PhD, provide a brief recap of recent developments with innovative targeted therapeutics in gastric cancer, including evidence presented at the 2020 American Society of Clinical Oncology Annual Meeting. Dr. Ilson comments on these findings and offers thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with gastric cancer.

David H. Ilson, MD, PhD, will be joined by Geoffrey Ku, MD, and Laura H. Tang, MD, PhD, as expert presenters for this educational activity.

Watch Now

Transforming Gastric Cancer Practice: HER2-Targeted and Other Novel Agents

1.0 CME/MOC

Watch this video from a recent webcast in which a panel of experts reviewed the importance of biomarker testing, the latest evidence on targeted therapies, and strategies to effectively integrate new and novel approaches into practice. In segments called “Translating Science, Transforming My Practice,” the experts will offer a personal look at the expanding therapeutic approaches and ongoing research in gastric cancer care and what the emergence of new therapeutics means for their practices.

Regional Meetings

Live: HER2-Targeted and Other Novel Therapies in Gastric Cancer

1.0 CME/MOC

Have one of our experts lead a live meeting at your institution and learn about recent therapeutic advances in management of patients with gastric cancer. Hear expert perspectives on the practical aspects of caring for patients with gastric cancer, and learn the potential clinical implications of integrating new and novel targeted agents into practice.

Curriculum Description

Gastric/gastroesophageal junction (GEJ) cancer is a heterogeneous and aggressive malignancy. Fortunately, an increased understanding of carcinogenesis pathways, such as VEGF, and actionable genetic alterations in gastric cancer, such as HER2 amplification, PD-L1 amplification and MSI/MMR status, has transformed the management to become more patient-centered with individualized, targeted therapies.

As the management of gastric/GEJ cancer is rapidly evolving, oncologists and other healthcare professionals will benefit from receiving practical guidance on the role and use of current and emerging personalized therapies. PeerView has developed this collection of educational activities to highlight the importance of molecular testing, help synthesize the latest advances and data of novel HER2-directed and other targeted therapeutics, and offer optimal strategies to effectively integrate personalized medicine in gastric cancer care.

Target Audience

These activities have been designed to meet the educational needs of oncologists and other clinicians involved in the management of gastric cancer.

PeerView Live - Request a Meeting

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

How will recent therapeutic advances in management of gastric cancer affect your clinical practice? Request a live in-person meeting at your institution or a live virtual webinar and have an expert provide perspectives on the practical aspects of caring for patients with gastric cancer in a small group setting. Don’t miss this opportunity to get answers to your questions on integrating new and novel targeted agents into practice.

Download and complete the Meeting Request Form (or complete our online form) to request a live in-person meeting or turn-key virtual meeting with our expert faculty.

By requesting a meeting, you are attesting that you have read the CME/MOC Information for this activity.

Request a Meeting at Your Institution!Download CME/MOC Information & Meeting Request Form